Skip to main content

Table 2 Univariate analysis (upper column) and multivariate analysis (lower column) using Cox regression

From: Impact of tumor attachment to the pleura measured by a pretreatment CT image on outcome of stage I NSCLC treated with stereotactic body radiotherapy

Variables

In-field control

Locoregional control

Freedom from distant metastasis

Freedom from progression

P value

HR

95% CI

P value

HR

95% CI

P value

HR

95% CI

P value

HR

95% CI

Attachment status: broad attachment vs. others

<0.01*

11.5

2.42-81.5

<0.01*

4.60

1.91-10.8

0.01*

3.02

1.22-7.19

<0.01*

3.78

1.87-7.40

Gender: female vs. male

0.89

1.11

0.15-5.20

0.29

0.57

0.16-1.54

0.57

1.29

0.49-3.03

0.54

0.79

0.35-1.62

Diagnosis: pathological vs. clinical

0.17

3.59

0.60-68.1

0.15

2.00

0.78-6.13

0.19

1.81

0.75-5.09

0.11

1.79

0.87-4.04

Tumor diameter (cm): per 1 cm increase

<0.01*

3.71

1.47-9.72

<0.01*

2.25

1.30-3.83

<0.01*

2.01

1.19-3.33

<0.01*

2.02

1.32-3.07

Perfomance status: 0-1 vs. 2-3

0.97

0.96

0.15-18.5

0.88

1.09

0.36-4.71

0.38

1.81

0.52-11.3

0.48

1.42

0.56-4.81

SBRT dose (BED10): > 102 Gy10 vs. ≤ 102 Gy10

0.02*

0.13

0.01-0.79

0.59

1.25

0.54-3.05

0.88

0.94

0.45-2.02

0.77

0.90

0.47-1.75

Prescription: isocenter vs. D95

0.53

1.88

0.30-36.3

0.94

0.96

0.35-3.01

0.79

0.88

0.35-2.48

0.27

0.64

0.30-1.45

Attachment status: broad attachment vs. others

0.15

4.00

0.59-35.6

0.02*

3.08

1.15-8.27

0.19

1.93

0.70-5.29

0.01*

2.66

1.21-5.73

Tumor diameter (cm): per 1 cm increase

0.04*

3.65

1.00-14.1

0.12

1.67

0.86-3.10

0.09

1.68

0.91-3.00

0.06

1.59

0.96-2.55

SBRT dose (BED10): > 102 Gy10 vs. ≤ 102 Gy10

0.02*

0.10

0.01-0.75

n.s.

  

n.s.

  

n.s

  
  1. Abbreviations: D95, doses covering 95% of the planning target volume; BED, biological effective dose; HR, hazard ratio; CI, confidence interval; n.s, not significant. *p < 0.05.